Fibroblast Growth Factor 21 Mediates Glycemic Regulation by Hepatic JNK

Cell Reports

Volumn 14, Issue 10, 2016, Pages 2273-2280

  Vernia, Santiago ^a,d   Cavanagh Kyros, Julie ^a,b   Barrett, Tamera ^a,b   Tournier, Cathy ^c   Davis, Roger J ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; STRESS ACTIVATED PROTEIN KINASE; EHHADH PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11; PEROXISOMAL BIFUNCTIONAL ENZYME; PROTEIN KINASE INHIBITOR; RESISTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVATION; ENZYME REGULATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IMPAIRED GLUCOSE TOLERANCE; LIPID DIET; LIVER CELL; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; ADIPOSE TISSUE; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; MALE; METABOLIC DISEASES; METABOLISM; OBESITY; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIET, HIGH-FAT; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HEPATOCYTES; INSULIN; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEPTIN; MALE; MAP KINASE KINASE KINASES; METABOLIC DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; PEROXISOMAL BIFUNCTIONAL ENZYME; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RESISTIN; SIGNAL TRANSDUCTION;

EID: 84960355087     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.026     Document Type: Article

References (35)

1. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
2. Badman M.K., Koester A., Flier J.S., Kharitonenkov A., Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
3. Belgardt B.F., Mauer J., Wunderlich F.T., Ernst M.B., Pal M., Spohn G., Brönneke H.S., Brodesser S., Hampel B., Schauss A.C., Brüning J.C. Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism. Proc. Natl. Acad. Sci. USA 2010, 107:6028-6033.
4. Chartoumpekis D.V., Ziros P.G., Psyrogiannis A.I., Papavassiliou A.G., Kyriazopoulou V.E., Sykiotis G.P., Habeos I.G. Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes 2011, 60:2465-2473.
5. De Sousa-Coelho A.L., Marrero P.F., Haro D. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem. J. 2012, 443:165-171.
6. Dong J.Q., Rossulek M., Somayaji V.R., Baltrukonis D., Liang Y., Hudson K., Hernandez-Illas M., Calle R.A. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br. J. Clin. Pharmacol. 2015, 80:1051-1063.
7. Douris N., Stevanovic D.M., Fisher F.M., Cisu T.I., Chee M.J., Nguyen N.L., Zarebidaki E., Adams A.C., Kharitonenkov A., Flier J.S., et al. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 2015, 156:2470-2481.
8. Emanuelli B., Vienberg S.G., Smyth G., Cheng C., Stanford K.I., Arumugam M., Michael M.D., Adams A.C., Kharitonenkov A., Kahn C.R. Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Invest. 2014, 124:515-527.
9. Fisher F.M., Chui P.C., Nasser I.A., Popov Y., Cunniff J.C., Lundasen T., Kharitonenkov A., Schuppan D., Flier J.S., Maratos-Flier E. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014, 147:1073-1083.
10. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L., Kharitonenkov A., Bumol T., Schilske H.K., Moller D.E. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013, 18:333-340.
11. Han M.S., Jung D.Y., Morel C., Lakhani S.A., Kim J.K., Flavell R.A., Davis R.J. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science 2013, 339:218-222.
12. Holland W.L., Adams A.C., Brozinick J.T., Bui H.H., Miyauchi Y., Kusminski C.M., Bauer S.M., Wade M., Singhal E., Cheng C.C., et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013, 17:790-797.
13. Hotta Y., Nakamura H., Konishi M., Murata Y., Takagi H., Matsumura S., Inoue K., Fushiki T., Itoh N. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009, 150:4625-4633.
14. Iizuka K., Takeda J., Horikawa Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett. 2009, 583:2882-2886.
15. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
16. Kant S., Barrett T., Vertii A., Noh Y.H., Jung D.Y., Kim J.K., Davis R.J. Role of the mixed-lineage protein kinase pathway in the metabolic stress response to obesity. Cell Rep. 2013, 4:681-688.
17. Kim K.H., Jeong Y.T., Oh H., Kim S.H., Cho J.M., Kim Y.N., Kim S.S., Kim do H., Hur K.Y., Kim H.K., et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 2013, 19:83-92.
18. Kwon M.M., O'Dwyer S.M., Baker R.K., Covey S.D., Kieffer T.J. FGF21-mediated improvements in glucose clearance require uncoupling protein 1. Cell Rep. 2015, 13:1521-1527.
19. Li Y., Wong K., Giles A., Jiang J., Lee J.W., Adams A.C., Kharitonenkov A., Yang Q., Gao B., Guarente L., Zang M. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014, 146:539-549.
20. Liang Q., Zhong L., Zhang J., Wang Y., Bornstein S.R., Triggle C.R., Ding H., Lam K.S., Xu A. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 2014, 63:4064-4075.
21. Lin Z., Tian H., Lam K.S., Lin S., Hoo R.C., Konishi M., Itoh N., Wang Y., Bornstein S.R., Xu A., Li X. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013, 17:779-789.
22. Markan K.R., Naber M.C., Ameka M.K., Anderegg M.D., Mangelsdorf D.J., Kliewer S.A., Mohammadi M., Potthoff M.J. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014, 63:4057-4063.
23. Owen B.M., Ding X., Morgan D.A., Coate K.C., Bookout A.L., Rahmouni K., Kliewer S.A., Mangelsdorf D.J. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014, 20:670-677.
24. Owen B.M., Mangelsdorf D.J., Kliewer S.A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 2015, 26:22-29.
25. Potthoff M.J., Kliewer S.A., Mangelsdorf D.J. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012, 26:312-324.
26. Sabio G., Davis R.J. cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance. Trends Biochem. Sci. 2010, 35:490-496.
27. Sabio G., Das M., Mora A., Zhang Z., Jun J.Y., Ko H.J., Barrett T., Kim J.K., Davis R.J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
28. Sabio G., Cavanagh-Kyros J., Barrett T., Jung D.Y., Ko H.J., Ong H., Morel C., Mora A., Reilly J., Kim J.K., Davis R.J. Role of the hypothalamic-pituitary-thyroid axis in metabolic regulation by JNK1. Genes Dev. 2010, 24:256-264.
29. Sabio G., Kennedy N.J., Cavanagh-Kyros J., Jung D.Y., Ko H.J., Ong H., Barrett T., Kim J.K., Davis R.J. Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulin resistance. Mol. Cell. Biol. 2010, 30:106-115.
30. Tanaka N., Takahashi S., Zhang Y., Krausz K.W., Smith P.B., Patterson A.D., Gonzalez F.J. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. Biochim. Biophys. Acta 2015, 1852:1242-1252.
31. Tournier C., Dong C., Turner T.K., Jones S.N., Flavell R.A., Davis R.J. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 2001, 15:1419-1426.
32. Vernia S., Cavanagh-Kyros J., Barrett T., Jung D.Y., Kim J.K., Davis R.J. Diet-induced obesity mediated by the JNK/DIO2 signal transduction pathway. Genes Dev. 2013, 27:2345-2355.
33. Vernia S., Cavanagh-Kyros J., Garcia-Haro L., Sabio G., Barrett T., Jung D.Y., Kim J.K., Xu J., Shulha H.P., Garber M., et al. The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. Cell Metab. 2014, 20:512-525.
34. Ye D., Wang Y., Li H., Jia W., Man K., Lo C.M., Wang Y., Lam K.S., Xu A. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice. Hepatology 2014, 60:977-989.
35. Zhang T., Inesta-Vaquera F., Niepel M., Zhang J., Ficarro S.B., Machleidt T., Xie T., Marto J.A., Kim N., Sim T., et al. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol. 2012, 19:140-154.